ArticleOpen life sciences2025
High levels of EPHB2 expression predict a poor prognosis and promote tumor progression in endometrial cancer.
Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) exhibits increasing incidence and mortality, necessitating novel prognostic biomarkers and therapeutic targets. This study systematically investigates EPHB2 as a potential biomarker through comprehensive bioinformatics (TIMER 2.0, Human Protein Atlas, Xanadu Academic Online, Sento Academic Online, TCGA, GeneMANIA, GSEA, BEST database, and SCAR database) and experimental analyses (si-EPHB2 and OE-EPHB2 RL95-2 cell models with RT-qPCR, western blot, CCK-8, wound healing, Transwell, and TUNEL assays). Our findings demonstrate that EPHB2 is significantly overexpressed in EC, correlating with advanced pathological grade, histological type, and poor prognosis, while its high expression activates PI3K/AKT/MAPK signaling and promotes proliferation, migration, invasion, and suppresses apoptosis; conversely, EPHB2 knockdown exhibits opposite effects, revealing its critical role in EC progression through immune modulation and oncogenic signaling activation, thereby establishing EPHB2 as a promising therapeutic target for EC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.